Arrowhead Pharmaceuticals Schedules Two Key Webinars in January 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Businesswire
- Webinar Schedule: Arrowhead Pharmaceuticals is set to hold a KOL webinar on January 6, 2026, focusing on interim clinical data for ARO-INHBE and ARO-ALK7, aimed at showcasing its latest research advancements to key opinion leaders and enhancing market interest in its products.
- Healthcare Conference Participation: The company will also participate in the J.P. Morgan Healthcare Conference from January 12-15, 2026, where it will conduct a corporate presentation, further increasing investor awareness and confidence in its research pipeline.
- Information Access Channels: Presentation materials and webcast links will be made available on Arrowhead's website under the Investors section, ensuring timely access to the latest information for investors, thereby enhancing transparency and communication efficiency.
- Forward-Looking Statements: The press release includes forward-looking statements regarding expectations for future clinical trials and product pipelines, highlighting the company's confidence in future developments despite various uncertainties, which may impact investor sentiment positively.
ARWR
$69+Infinity%1D
Analyst Views on ARWR
Wall Street analysts forecast ARWR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARWR is 61.63 USD with a low forecast of 48.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 68.160
Low
48.00
Averages
61.63
High
85.00
Current: 68.160
Low
48.00
Averages
61.63
High
85.00
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
